← Back to Clinical Trials
Recruiting NCT07536568

NCT07536568 Sublingual Caffeine on Reducing Recovery Time and Postoperative Agitation in Elderly Patients Undergoing General Anesthesia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07536568
Status Recruiting
Phase
Sponsor Cairo University
Condition Sublingual
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2026-04-18
Primary Completion 2026-07-15

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Caffine citratePlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2026-04-18 with a primary completion date of 2026-07-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to evaluate the efficacy of sublingual caffeine in reducing recovery time and incidence of postoperative agitation in elderly patients undergoing general anesthesia.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 65 years. * Both sexes. * American Society of Anesthesiologists (ASA) physical status II. * Scheduled for elective ophthalmology surgery under general anesthesia. Exclusion Criteria: * History of severe cardiac arrhythmias or uncontrolled hypertension. * ASA III patients were excluded to reduce the risk of adverse events in elderly patients with severe systemic diseases. * Known allergy or hypersensitivity to caffeine. * Pre-existing cognitive impairment or dementia (All patients will undergo preoperative cognitive screening using the online Mini-Cog test or Montreal Cognitive Assessment \[MoCA\]). * History of seizures or epilepsy. * History of alcohol or drug abuse. * Chronic use of CNS stimulants or sedatives. * Emergency surgeries. * Prolonged procedures for more than 3 hours.

Contact & Investigator

Central Contact

Ghada A Sherif, MD

✉ drghadasherif@gmail.com

📞 00201006153615

Frequently Asked Questions

Who can join the NCT07536568 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Sublingual. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07536568 currently recruiting?

Yes, NCT07536568 is actively recruiting participants. Contact the research team at drghadasherif@gmail.com for enrollment information.

Where is the NCT07536568 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT07536568 clinical trial?

NCT07536568 is sponsored by Cairo University. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology